INDEMNIFICATION AGREEMENTIndemnification Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [____________] between Sagimet Biosciences Inc., a Delaware corporation (the “Company”), and [______________] (“Indemnitee”).
LEASE AGREEMENT between Casiopea Bovet, LLC “Landlord” and 3-V Biosciences, Inc., a Delaware corporation “Tenant”Lease Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Commencement Date: The Lease shall commence upon the later of substantial completion of the Tenant Improvements by Landlord or April 1, 2019.
Patent Assignment AgreementPatent Assignment Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Hong Kong
This Patent Assignment Agreement (this “Agreement”), effective as of October 25, 2019, is signed by and between Sagimet Biosciences Inc. (formerly known as 3-V Biosciences, Inc.), a corporation organized under the laws of Delaware, having a principal place of business at 155 Bovet Road Suite 303, San Mateo, CA 94402 (hereinafter referred as “Assignor” or “Sagimet”); and Gannex Pharma Co., Ltd. ( 甘莱制药有限公司), an affiliate of Ascletis BioScience Co., Ltd. (both wholly-owned subsidiaries of Ascletis Pharma Inc.) and a corporation under the laws of China having a registered office at No. 665 Zhangjiang Road, 3rd Floor, Shanghai Pilot Free Trade Zone, Shanghai, China (hereinafter referred to as "Assignee").
investors’ rights agreement’ Rights Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of December 21, 2020, by and among Sagimet Biosciences Inc., a Delaware corporation (the “Company”), and the investors listed on the Schedule of Investors attached as Exhibit A hereto (each, an “Investor,” and collectively, the “Investors”).
ContractStock Option Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
AMENDED AND RESTATED NOMINATING AGREEMENTNominating Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED NOMINATING AGREEMENT (this “Agreement”), dated as of April 15, 2021, by and among Sagimet Biosciences Inc., a Delaware corporation (the “Company”), Baker Brothers Life Sciences, L.P. (“BBLS”) and 667, L.P. (“667,” together with BBLS, the “Investor”).
